Abstract | DESIGN:
Pancreastatin, a novel peptide, is known to inhibit insulin secretion and to have a glycogenolytic effect, and is present in many endocrine and chromaffin cells. Both the plasma insulin levels and the adrenergic activity accompanying insulin resistance have been shown to be increased in hypertensive subjects. Our working hypothesis was that pancreastatin might play a role in these pathological phenomena. METHODS: RESULTS: CONCLUSIONS:
|
Authors | V Sánchez-Margalet, M Valle, J A Lobón, A Maldonado, F Escobar-Jimenez, J Oliván, R Pérez-Cano, R Goberna |
Journal | Journal of hypertension
(J Hypertens)
Vol. 13
Issue 2
Pg. 251-8
(Feb 1995)
ISSN: 0263-6352 [Print] England |
PMID | 7615956
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies
- Chromogranin A
- Pancreatic Hormones
- pancreastatin
- Glucose
|
Topics |
- Adult
- Antibodies
- Chromogranin A
- Fasting
- Female
- Glucose
(administration & dosage, metabolism)
- Glucose Tolerance Test
- Humans
- Hypertension
(metabolism)
- Male
- Middle Aged
- Pancreatic Hormones
(blood, immunology)
- Radioimmunoassay
|